GlassScriptPhysician profile
Robert Roy Byrne
NPI 1902805765
$7,394.32
in general payments reported to CMS, 2019-2025
60 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $514 · 2021: $1,010 · 2022: $1,008 · 2023: $1,142 · 2024: $1,092 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,370 · Travel and Lodging: $350 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,370.48 |
| Travel and Lodging | $350.44 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $747.48 | 2022-2025 | Urolift, Barrigel |
| Bayer Healthcare Pharmaceuticals INC. | $742.26 | 2020-2025 | |
| Astellas Pharma US INC | $699.78 | 2019-2025 | Xtandi |
| Janssen Biotech, INC. | $686.98 | 2019-2025 | Erleada |
| Dendreon Pharmaceuticals LLC | $420.67 | 2019-2024 | Provenge |
| Myriad Genetic Laboratories, INC. | $349.30 | 2021-2025 | Prolaris, Myrisk |
| Abbvie INC. | $298.51 | 2019-2025 | Botox |
| Blue Earth Diagnostics | $221.50 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $215.88 | 2023-2025 | Orgovyx, Gemtesa |
| Pfizer INC. | $215.10 | 2019-2025 | |
| Boston Scientific Corporation | $193.96 | 2019-2025 | Lithovue, General - Kidney Stone Disease, Spaceoar Vue System - 10ml |
| Urogen Pharma, INC. | $158.59 | 2020-2025 | Jelmyto |
| Endo Pharmaceuticals INC. | $153.86 | 2019-2023 | Aveed, Xiaflex |
| Amgen INC. | $152.62 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $148.92 | 2021-2025 | Imfinzi, Lynparza |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Byrne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.